Adverse reaction report
MENU
2024.01.23
Health Canada approves SinoT’s generic drug Posaconazole delayed-release tablets (100mg)
Read More
2023.11.02
On August 8, 2023, U.S. Food and Drug Administration(FDA)tentatively approved SinoT’s ANDA application for Tofacitinib Extended Release Tablet (ANDA #216001).
2023.06.05
Recently,Food and Drug Administration (FDA) approved SinoT’s ANDA(# 214496)application for PREGABALIN EXTENDED-RELEASE TABLETS(82.5 mg, 165 mg, and 330 mg)
2023.05.15
Recently,Food and Drug Administration (FDA) approved SinoT’s ANDA(#217337)application for Mesalamine, delayed-release tablets(1.2g).
2022.08.25
Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA
2022.04.07
Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been granted approval from the Health Sciences Authority (HSA) in Singapore.
2021.11.02
Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Bupropion hydrochloride extended-release tablets (XL)(150mg,300mg), this product has already been approved in FDA on August 2017.
2021.08.12
On August 11, 2021,Food and Drug Administration (FDA) approved SinoT’s ANDA(#213612)application for Paroxetine hydrochloride extended-release tablets(12.5mg,25mg).
Shanghai Head Office
86 21-6881-9009
99 Haike Road, Bldg. 3, 1st Flr., Pudong District Shanghai 201210, P.R. China
Manufacturing Site in Jiangsu
86 513-8122-1988
No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province
Focus on us
Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP:13048014-1 Powered by Yongsy
Privacy Legal